STOCK TITAN

GRI Bio (GRI) DEF 14A Filings

GRI NASDAQ

Here are the DEF 14A proxy statements from GRI Bio, Inc. (GRI) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow GRI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GRI filings page.

Rhea-AI Summary

GRI Bio, Inc. is soliciting stockholder votes for its virtual 2026 annual meeting on November 4, 2026. The ballot includes electing W. Marc Hertz, Ph.D. and David Szekeres as Class III directors through the 2029 annual meeting; ratifying WithumSmith+Brown, PC as independent auditor for fiscal 2026; a proposal to increase shares available for issuance under the 2018 Equity Incentive Plan by 546,529 shares and extend its evergreen provision to January 1, 2036; and authority to adjourn or postpone if additional proxies are needed. The board recommends FOR each proposal.

There were 2,186,115 common shares outstanding and entitled to vote as of September 22, 2026. The meeting will be held by live audio webcast at 11:00 a.m. Eastern Time, with voting available online, by telephone, by mail or during the meeting. Reported 2025 total compensation was $1,027,220 for CEO W. Marc Hertz, $584,722 for CFO Leanne Kelly and $579,087 for Chief Scientific Officer Vipin Kumar. The board has five directors, three determined independent, and the chair and CEO roles are separate.